Please assess the completion status of the following clinical trial:

Trial Title: Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnostic criteria for MDD (diagnosed with the use of SCID)~* Written informed consent~* Men or women aged 18-65~* A baseline Hamilton-D17 score of \> 16.~Exclusion Criteria:~* Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician. These patients will be immediately referred to appropriate clinical treatment.~* Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy)~* Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease~* History of seizure disorder,~* History or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, including alcohol, active within the last 12 months.~* History or current diagnosis of dementia, or a score of \< 26 on the Mini Mental Status Examination (Folstein, 1975) at the screening visit.~* History of multiple adverse drug reactions or allergy to the study drugs.~* Patients with mood congruent or mood incongruent psychotic features.~* Patients having shown minimal or no response to a standard course of antidepressant treatment with an SSRI. A standard course will be defined as the following medications taken for \> 4 weeks: fluoxetine \> 20 mg/day, sertraline \> 50 mg/day, paroxetine \> 20 mg/day, fluvoxamine \> 50 mg/day, citalopram \> 20 mg/day, venlafaxine \> 150 mg/day.~* Clinical or laboratory evidence of hypothyroidism.~* Patients who have had electroconvulsive therapy (ECT) within the 6 months preceding baseline.~* History of intolerance to Cytomel~* History of cardiac pathology or diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).